Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Mov Disord. 2022 Jul 16;37(9):1904–1914. doi: 10.1002/mds.29154

Figure 2.

Figure 2.

The estimated rates of progression among subjects in inosine and placebo groups in overall parkinsonian motor severity (from unidimensional longitudinal IRT models, A and C) and in tremor and non-tremor motor severities (from multidimensional longitudinal IRT model, B and D) in the pre-levodopa therapy dataset (A and B, time zero is the baseline visit) and in the levodopa therapy dataset (C and D, time zero is the visit when patients required levodopa medication).